• MEK/ERK Control of TERT Expression in Human Pluripotent Stem

  2026-04-19

  This study reveals how MEK1/2 kinases, together with c-Myc:MAX, maintain TERT transcription in human pluripotent stem cells by preventing polycomb-mediated repression. The findings clarify a crucial mechanism for telomerase regulation and have implications for stem cell maintenance and telomere biology.

• circ_0042103/TAF15/NER Axis Drives DNA Damage in Pulpitis

  2026-04-18

  This study uncovers a novel regulatory axis involving circ_0042103, TAF15, and the nucleotide excision repair pathway that exacerbates DNA damage and inflammation in pulpitis. The findings advance understanding of circular RNA function in dental pulp stem cells and highlight essential methodological considerations for circular RNA enrichment.

• PERK-JAK1–STAT3 Pathway Links ER Stress to Pyroptosis in Dis

  2026-04-17

  This study uncovers how excessive endoplasmic reticulum (ER) stress drives inflammatory cell death (pyroptosis) in nucleus pulposus cells via PERK-dependent JAK1–STAT3 activation, providing mechanistic insight into intervertebral disc degeneration. The findings highlight the therapeutic potential of targeting ER stress signaling to mitigate disc inflammation and degeneration.

• Oteseconazole (VT-1161): Precision Antifungal for Candida Co

  2026-04-16

  Oteseconazole (VT-1161) is a selective CYP51 inhibitor showing potent, low-MIC antifungal activity against Candida species. Its high selectivity minimizes human P450 interactions, supporting its use in recurrent vulvovaginal candidiasis prevention. Efficacy extends to fluconazole-resistant isolates, with minimal activity against Aspergillus.

• Hesperadin: Applied Workflows for Aurora B Kinase Inhibition

  2026-04-15

  Hesperadin enables precise, ATP-competitive Aurora B kinase inhibition, uniquely facilitating studies of mitotic progression and spindle assembly checkpoint disruption. This guide delivers actionable protocols, troubleshooting strategies, and data-driven insights for leveraging Hesperadin in advanced cancer and cell cycle research.

• Metabolomics Reveals Resistance Mechanisms in Carbapenemase-

  2026-04-14

  This study applies LC-MS/MS metabolomics to differentiate carbapenemase-producing Enterobacterales based on metabolic signatures, enabling rapid discrimination of resistant versus non-resistant phenotypes. The findings offer new insights for diagnostic assay development and deepen mechanistic understanding of carbapenem resistance.

• Sulfo-Cy3 NHS Ester: Illuminating Vascular Remodeling Pathwa

  2026-04-13

  Explore how Sulfo-Cy3 NHS Ester empowers translational researchers to uncover the mechanisms of vascular remodeling and collateral circulation, with mechanistic and workflow guidance anchored to recent peer-reviewed insights.

• Valemetostat (DS-3201): Precision EZH2 Inhibition in Lymphom

  2026-04-12

  Valemetostat (DS-3201) empowers researchers to interrogate EZH2-driven epigenetic mechanisms in lymphoma models with high selectivity—even across wild-type and mutant variants. This guide distills actionable protocols, workflow upgrades, and troubleshooting strategies to accelerate translational breakthroughs using this next-generation oral EZH2 inhibitor.

• IGFBP2–THBS1 Axis: Redefining Growth Hormone Research Strate

  2026-04-12

  This article provides a thought-leadership perspective for translational researchers, unpacking the mechanistic and strategic significance of the IGFBP2–THBS1 regulatory axis in growth hormone biology. Leveraging the latest peer-reviewed evidence, we elucidate how APExBIO’s Recombinant Human Growth Hormone (GH) empowers experimental innovation, particularly in idiopathic short stature and chondrocyte signaling. The discussion bridges molecular insight, validated protocols, and actionable guidance for advancing growth hormone research beyond conventional paradigms.

• ARCA Cy3 EGFP mRNA (5-moUTP): Advancing Fluorescent mRNA Del

  2026-04-11

  ARCA Cy3 EGFP mRNA (5-moUTP) combines 5-methoxyuridine modification and Cy3 labeling for direct, high-sensitivity mRNA tracking in mammalian cells. This APExBIO reagent streamlines delivery optimization, immune evasion, and real-time analysis—enabling translational researchers to troubleshoot and enhance mRNA-based workflows with precision.

• LDN-193189: ALK Inhibitor Workflows for BMP Pathway Research

  2026-04-11

  LDN-193189 is the benchmark ALK inhibitor for precise BMP type I receptor inhibition, streamlining Smad1/5/8 pathway studies and epithelial barrier models. This guide translates new reference breakthroughs and industry best practices into actionable protocol enhancements and troubleshooting tactics for cell and animal assays.

• Palonosetron Hydrochloride: Precision 5-HT3 Receptor Anta...

  2026-04-10

  Palonosetron hydrochloride is a highly selective 5-HT3 receptor antagonist, clinically validated for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting (CINV/RINV). Its dual mechanism and long half-life deliver sustained antiemetic efficacy, making it a benchmark compound for research and clinical application.

• Triiodothyronine (T3) in Metabolic Regulation: Reliable S...

  2026-04-09

  This article addresses key laboratory challenges in metabolic disorder and thyroid hormone signaling research, focusing on reproducible cell viability and differentiation assays. Drawing on scenario-driven Q&A blocks and recent literature, it demonstrates how Triiodothyronine (SKU C6407) delivers data-backed reliability, assay sensitivity, and workflow compatibility for biomedical researchers.

• Triiodothyronine (T3) for Metabolic Regulation and Adipoc...

  2026-04-08

  Triiodothyronine (T3) is transforming metabolic disorder research by enabling precise control of thyroid hormone receptor signaling and cellular metabolism assays. APExBIO’s high-purity T3 (SKU C6407) empowers scientists to reliably dissect gene expression modulation, adipocyte differentiation, and endocrine pathway dynamics—delivering reproducibility from bench to breakthrough.

• Palonosetron Hydrochloride: High-Selectivity 5-HT3 Recept...

  2026-04-08

  Palonosetron hydrochloride is a highly selective 5-HT3 receptor antagonist with sub-nanomolar potency and an extended duration of action, making it a preferred agent for chemotherapy- and radiotherapy-induced nausea and vomiting prevention. Its dual allosteric and orthosteric binding, minimal off-target activity, and favorable pharmacokinetics are supported by robust in vitro and in vivo benchmarks.

450 records 21/30 page Previous Next First page 上5页 2122232425 下5页 Last page